Atomo Diagnostics (AT1.AX) Action Cours

Atomo Diagnostics Ltd, trading under the ticker symbol AT1.AX and identified by ISIN AU0000080327, is an Australian health care company headquartered in Sydney. The firm went public on April 16, 2020, and operates through its official website at https://www.atomodiagnostics.com/. The company is primarily engaged in the manufacturing, research, development, and design of in-vitro medical devices. These devices are specifically engineered for blood-based rapid diagnostic testing, serving both professional medical use and self-testing applications. Atomo Diagnostics supplies integrated rapid diagnostic test devices to the global diagnostic market, aiming to simplify testing procedures while enhancing usability and improving reliability across various point-of-care and at-home testing scenarios. The company has successfully commercialized a number of products across international markets and has established supply agreements for testing applications that target infectious diseases. These applications include testing for COVID-19, differentiation between viral and bacterial infections, and female health monitoring. Among its key product offerings are the Atomo HIV Self-Test, the AtomoRapid HIV (1&2), and the ATOMONOW Pregnancy Test. The Atomo HIV Self-Test is an integrated, blood-based rapid diagnostic test designed for HIV screening. It provides results in just 15 minutes, offering a convenient solution for individuals seeking private and rapid health information. The AtomoRapid HIV (1&2) device integrates multiple test components into a single platform, requiring only a small drop of blood to deliver results within 15 minutes. This design simplifies the testing process and enhances the reliability of the outcomes. By focusing on innovative device design and efficient manufacturing processes, Atomo Diagnostics aims to address critical gaps in global health diagnostics. The company's technology is particularly relevant in contexts where rapid, accurate, and accessible testing is essential for effective disease management and public health initiatives. Through its commitment to research and development, the firm continues to expand its portfolio of diagnostic solutions, catering to both professional healthcare providers and individual consumers seeking reliable self-testing options.